In the fall, Finn went off to school in San Diego as planned. It was an exciting time in cancer research particularly. The work was translational, taking leading-edge basic science findings and applying them in the clinic, another aspect of the work that appealed to Finn. He decided that this was what he would do — cancer research.
Finn left UCLA to attend medical school at USC, but he kept in touch and continued to work in the lab during the school years and summers. He returned to UCLA for his residency and fellowship and joined the faculty in He specializes in breast and liver cancers, spending about 20 percent of his time in the clinic seeing patients and 80 percent in the lab. Finn and his team are looking to find molecular alterations like HER-2 in other cancers, so targeted therapies can be developed to home in on the cancer cells and leave the healthy tissue alone.
Population: Pediatrics. This is a prospective randomized clinical trial, to determine whether dose- intensive tandem Consolidation, in a randomized comparison with single cycle Consolidation, provides an event-free survival EFS and overall survival OS.
The study population will be high-risk patients non-Wnt and non-Shh sub-groups with medulloblastoma, and for all patients with central nervous system CNS embryonal tumors completing Head Start 4 Induction. This study will further determine whether the additional labor intensity duration of hospitalizations and short-term and long-term morbidities associated A randomized phase III trial evaluating the role of axillary lymph node dissection in breast cancer patients cT N1 who have positive sentinel lymph node disease after neoadjuvant chemotherapy.
Phase: III. The lymph nodes in the arm pit are examined during surgery and if there is still cancer in the lymph nodes, then the majority of lymph nodes in the arm pit are removed.
The purpose of this study is to examine whether removing some of the lymph nodes from the arm pit, but not removing them all followed with radiation therapy experimental will be as good as having the majority of the lymph nodes For some patients, this may include no treatment and only close observation. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is.
This may help to avoid some of the risks and side effects related to Principal Investigator: Andrew B. Lassman, MD. The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy.
Safety and how well you can tolerate the drug will be determined on the basis of physical exams, laboratory tests, and questions about any problems you might experience during the study. Are you Eligible?
Childhood Cancer Genomics. Study Findings. Metastatic Cancer Research. Intramural Research. Extramural Research. Cancer Research Workforce. Partners in Cancer Research. What Are Cancer Research Studies. Research Studies. Get Involved.
Cancer Biology Research. Cancer Genomics Research. Research on Causes of Cancer. Cancer Prevention Research. Cancer Treatment Research. Cancer Health Disparities. Childhood Cancers Research. Global Cancer Research. Cancer Research Infrastructure. Clinical Trials. Frederick National Laboratory for Cancer Research. Bioinformatics, Big Data, and Cancer. Annual Report to the Nation.
Research Advances by Cancer Type. Stories of Discovery. Milestones in Cancer Research and Discovery. Biomedical Citizen Science. Director's Message. Budget Proposal. Stories of Cancer Research. Driving Discovery. Highlighted Scientific Opportunities.
Research Grants. Research Funding Opportunities. Cancer Grand Challenges. Research Program Contacts.
0コメント